FindMyKOL

Jairo Melo, MD

Basic profile

Pulmonary Disease

ORCIDNone on fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionSan Antonio, TX · South CentralSpecialtyPulmonary DiseaseFocusRespiratory
Active KOLFindMyKOL type: RegionalLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Jairo Melo is a Respiratory physician. OpenAlex indexes 12 publications with 426 citations (h-index 7).

Overview

Scholarship

indexed output and impact (OpenAlex)
12publications

Publications indexed by OpenAlex. Counts exclude supporting files.

426citations

Citations across these publications.

7h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
44companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓

Industry payments

44 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • Actelion Pharmaceuticals US, Inc.
    Program year20256 payments
    $314
  • Merck Sharp & Dohme LLC
    Program year202512 payments
    $291
  • AstraZeneca Pharmaceuticals LP
    Program year202510 payments
    $186
All 95 payment records: search, sort and filter.Explore →

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Respiratory

    36.8%
    Corticosteroid22.8%
    Trelegy Ellipta66%Breo Ellipta22%Breztri Aerosphere6%Symbicort6%
    Part D<11 patients
    Leukotriene Receptor Antagonist8.5%
    Montelukast Sodium100%
    Part D≥29 patients

    + 2 more classes in this area

  • Cardiovascular

    26.8%
    Endothelin Receptor Antagonist17.9%
    Opsumit79%Ambrisentan21%
    Part D<11 patients
    Soluble Guanylate Cyclase Stimulator5.8%
    Adempas100%
    Part D<11 patients

    + 1 more class in this area

  • Genitourinary & hormones

    9.9%
    Phosphodiesterase 5 Inhibitor9.9%
    Sildenafil Citrate56%Tadalafil44%
    Part D<11 patients
Where care is delivered (Part B)37.9% facility · 62.1% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”